Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021424 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer
A Phase 1 study, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00021424 is a Phase 1 study that has completed, run by National Institute on Deafness and Other Communication Disorders (NIDCD).
The verdict
NCT00021424, a Phase 1 study, has completed, sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
Interventions
- BIOLOGICAL recombinant fowlpox-TRICOM vaccine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00021424
The ClinicalTrials.gov registry entry for NCT00021424 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant fowlpox-TRICOM vaccine is the first listed.
NCT00021424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00021424 about?
NCT00021424 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have stage IV head and neck cancer.
What is the current status of trial NCT00021424?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-06.
What interventions are being tested in trial NCT00021424?
The interventions under investigation include: recombinant fowlpox-TRICOM vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021424?
This trial is sponsored by National Institute on Deafness and Other Communication Disorders (NIDCD), which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.